Back

mr. ing. T.U.U. (Karijn) Vels

mr. ing. T.U.U. (Karijn) Vels

Full Professor
mr. ing. T.U.U. (Karijn) Vels
  • Department of Medical Oncology

Biography

Biography

Karijn Suijkerbuijk is a translational medical oncologist with special interest in melanoma and immunotherapy. During her PhD, she performed research on tumor epigenetics in breast cancer in the lab of Professor Saraswati Sukumar at the Sidney Kimmel Cancer Center at Johns Hopkins University. Dr. Suijkerbuijk currently participates in multiple phase II and III clinical trials on immune checkpoint inhibitors. She published papers in Oncogene, Annals of Oncology and JNCI, received research grants from KWF and NWO and was awarded an ASCO Merit Award. Her current research focuses on clinical and immunological parameters assoaciated with immune related adverse events during checkpoint inhibition and clinicopathological factors associated with checkpoint inhibitor response.

Side Activities

2022-... Member ESMO Real World Data Working Group

2022   Research funding Bristol Myers Squibb

2021-.. Scientific advisory board Maarten vd Weijden foundation

2021-..  ESMO melanoma faculty

2021     Organizer and chair Oncode Melanoma Workshop

2021     Reserach funding TigaTx

2020-.. Data Safety Monitoring Board CHOPIN study (LUMC)

2020    Data Safety Monitoring Board ICRA study (NKI)

2020-..  Member Dutch working group Cancer in Pregnancy

2020-.. Congress organization Immune-oncology symposium

2020  Research funding Novartis

2019-.. Scientific chair Dutch Melanoma Treatment Registry (DMTR)

2019-.. Advisory board member patient society Stichting Melanoom

2019-.. Board member Dutch Melanoma Tumor Focus Group

2018-.. Invited discussant Medtalks

Fellowship and Awards

2007  Research year for residents (UU2007-3977) KWF
2008  Translational grant KWF (UU-2008-4217
2008  AGIKO stipend, ZonMW
2008  ASCO Merit Award

2018 ZonMW goed gebruik geneesmiddelen

Research Output (97)

Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma:A Nation-Wide Study of the Dutch Melanoma Treatment Registry

Rauwerdink Daan Jan Willem, van Doorn Remco, van der Hage Jos, Van den Eertwegh Alfonsus J M, Haanen John B A G, Aarts Maureen, Berkmortel Franchette, Blank Christian U, Boers-Sonderen Marye J, De Groot Jan Willem B, Hospers Geke A P, de Meza Melissa, Piersma Djura, Van Rijn Rozemarijn S, Stevense Marion, Van der Veldt Astrid, Vreugdenhil Gerard, Wouters Michel W J M, Suijkerbuijk Karijn, van der Kooij Monique, Kapiteijn Ellen 19 Nov 2022, In: Cancers. 14

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

van Not Olivier J, Blokx Willeke A M, van den Eertwegh Alfons J M, de Meza Melissa M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion, van der Veldt Astrid A M, Boers-Sonderen Marye J, Jansen Anne M L, Wouters Michel W J M, Suijkerbuijk Karijn P M Sep 2022, In: JCO Precision Oncology. 6

End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma:A Nationwide Cohort Study

van Breeschoten Jesper, Ismail Rawa K, Wouters Michel W J M, Hilarius Doranne L, de Wreede Liesbeth C, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion A, van der Veldt Astrid A M, Vreugdenhil Gerard, Boers-Sonderen Marye J, Suijkerbuijk Karijn P M, UMC Amsterdam 9 Aug 2022, In: JCO oncology practice. 18 , p. e1611-e1620

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors

Ismail Rawa K, Suijkerbuijk Karijn P M, de Boer Anthonius, van Dartel Maaike, Hilarius Doranne L, Pasmooij Anna M J, van Zeijl Michiel C T, Aarts Maureen J B, van den Berkmortel Franchette W P J, Blank Christian U, Boers-Sonderen Marye J, de Groot Jan W B, Haanen John B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, van der Veldt Astrid A M, Vreugdenhil Art, Westgeest Hans, van den Eertwegh Alfons J, Wouters Michel W J M 6 Jun 2022, In: Melanoma Research. 32 , p. 460-468 9 p.

Response to immune checkpoint inhibitors in acral melanoma:A nationwide cohort study

van Not Olivier J, de Meza Melissa M, van den Eertwegh Alfons J M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, van Breeschoten Jesper, de Groot Jan-Willem B, Hospers Geke A P, Ismail Rawa K, Kapiteijn Ellen, Piersma Djura, van Rijn Roos S, Stevense-den Boer Marion A M, van der Veldt Astrid A M, Vreugdenhil Gerard, Bonenkamp Han J, Boers-Sonderen Marye J, Blokx Willeke A M, Wouters Michel W J M, Suijkerbuijk Karijn P M 4 Apr 2022, In: European Journal of Cancer. 167 , p. 70-80 11 p.

Diagnostic pitfalls after COVID-19 vaccination in melanoma and breast cancer patients:A case series

de Bock Ellen, Trumpi Kari, Suijkerbuijk Karijn P.M., Vriens Menno R., Richir Milan C. Apr 2022, In: International Journal of Surgery Case Reports. 93 , p. 1-5

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients:a propensity-matched survival analysis

van Breeschoten Jesper, Wouters Michel W J M, Hilarius Doranne L, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan-Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Roos S, Suijkerbuijk Karijn P M, Blokx Willeke A M, Tije Bert-Jan J Ten, Veldt Astrid A M van der, Vreugdenhil Art, Boers-Sonderen Marye J, van den Eertwegh Alfonsus J M 7 Mar 2022, In: British Journal of Cancer. 126 1 p.

The unfavorable effects of COVID-19 on Dutch advanced melanoma care

Van Not Olivier J, van Breeschoten Jesper, van den Eertwegh Alfonsus J M, Hilarius Doranne L, De Meza Melissa M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Ismail Rawa K, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion A M, van der Veldt Astrid A M, Vreugdenhil Gerard, Boers-Sonderen Marye J, Blokx Willeke A M, Suijkerbuijk Karijn P M, Wouters Michel W J M 1 Mar 2022, In: International Journal of Cancer. 150 , p. 816-824 9 p.

Nipple Aspirate Fluid at a Glance

Patuleia Susana I S, Suijkerbuijk Karijn P M, van der Wall Elsken, van Diest Paul J, Moelans Cathy B 29 Dec 2021, In: Cancers. 14 , p. 1-21

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs

Franken M. G., Leeneman B., Aarts M. J.B., van Akkooi A. C.J., van den Berkmortel F. W.P.J., Boers-Sonderen M. J., van den Eertwegh A. J.M., de Groot J. W.B., Hospers G. A.P., Kapiteijn E., Piersma D., van Rijn R. S., Suijkerbuijk K. P.M., van der Veldt A. A.M., Westgeest H. M., Wouters M. W.J.M., Haanen J. B.A.G., Uyl-de Groot C. A. Dec 2021, In: ESMO open. 6

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not